The exchange of medical knowledge is a founding principle of Mayo Clinic. William J. Mayo, M.D., said it best: “It is a great thing to make scientific discoveries of rare value, but it is even greater to be willing to share these...
The exchange of medical knowledge is a founding principle of Mayo Clinic. William J. Mayo, M.D., said it best: “It is a great thing to make scientific discoveries of rare value, but it is even greater to be willing to share these...
April 2023 - Cellular Therapy and Transfusion Medicine - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case’s sub-specialties are Cellular Therapy and Transfusion Medicine.
Improving diagnosis of rare congenital disorders - Insights
Experts at Mayo Clinic have developed a unique method of testing that combines new technology with novel bioinformatics to promptly detect a group of uncommon genetic conditions that are often difficult to identify.
Inflammatory Bowel Disease - Mayo Clinic Laboratories
Inflammatory bowel disease (IBD) is typically classified as either Crohn's disease or ulcerative colitis based on clinical features, colonoscopy findings, histologic changes, and the anatomical distribution of disease. In some cases,...
Biologic Therapy Testing - Mayo Clinic Laboratories
To monitor for immunogenicity, our reflexive approach first measures the biologic concentration within a patient’s specimen. Then, if necessary, an additional test is performed to assess the presence of antibodies to a specific drug that...
Communiqué Archives - Page 3 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
Find out how our hereditary cancer panels use next-generation sequencing to evaluate dozens of genes associated with cancer risk.
Learn about how our testing for patients with renal, bladder, and prostate cancer identifies the cancer’s genetic traits and helps direct treatment.
Myeloproliferative neoplasms - Insights
Learn about our reflexive molecular testing protocols that are designed to guide proper utilization of myeloproliferative neoplasms.